Contribute Try STAT+ Today

The New Mexico attorney general has filed a lawsuit against Gilead Sciences (GILD) and two other major drug makers for allegedly conspiring to block competition to several different HIV medicines, which ultimately caused the state to spend millions of dollars for “excessively overpriced” treatments.

Specifically, the lawsuit details a complicated scheme in which Gilead “deliberately and deceitfully” delayed generic competition for its widely used HIV medicines for several years by, among other things, reaching purportedly anticompetitive agreements with Bristol Myers Squibb (BMY) and Teva Pharmaceuticals (TEVA), which is one of the world’s largest purveyors of generic drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.